Guardant Health, Inc. GH
Set alert
At close · Oct 30
After hours · Oct 30, 4:03 PM ET
- YTD
- +75.05%
- 1 year
- +93.49%
- Open
- 182.48
- Prev close
- 185.31
- Mkt cap
- 23.99B
- Vol
- 1.50M
- Avg vol
- 1.94M
- EPS
- -3.50
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 175.44
- High
- 185.65
- Forward P/E
- -471.56
- Beta
- 1.58
- Short ratio
- 6.12
- Inst. own
- 100.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 169.49
- 200-d avg
- 130.15
- 1y target
- 202.24
5D chart
Events in this range
- Oct 27, 2026Rating: BTIG · Buy → Buy
Signals (130)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:05 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:05 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:40 PM | 1 day ago |
| RSI: Oversold | Oct 30, 2:30 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:25 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:00 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 1:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 1:15 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:30 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:20 PM | 1 day ago |
| RSI: Oversold | Oct 30, 12:00 PM | 1 day ago |
| RSI: Oversold | Oct 30, 11:40 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:25 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:00 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:30 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 1 day ago |
| RSI: Oversold | Oct 30, 9:30 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:20 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:20 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:35 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:55 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 12:40 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:05 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:55 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 10:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:45 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 9:45 AM | 2 days ago |
| SMA: Bearish | Oct 29, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| RSI: Oversold | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 12:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 11:55 AM | 3 days ago |
| SMA: Bearish | Oct 28, 11:30 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:20 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 11:10 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 10:55 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:40 AM | 3 days ago |
| SMA: Bearish | Oct 28, 10:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 28, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 12:45 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 27, 11:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 11:25 AM | 4 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:20 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bullish | Oct 26, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| RSI: Oversold | Oct 26, 3:20 PM | 5 days ago |
| RSI: Oversold | Oct 26, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:25 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 26, 11:35 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 5 days ago |
News
2 days ago zacks.com
Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 days ago businesswire.com
Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance…
4 days ago seekingalpha.com
Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well…
-
4 days ago benzinga.com
BTIG Maintains Buy on Guardant Health, Raises Price Target to $210
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.
1 week ago benzinga.com
This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.
-
1 week ago benzinga.com
Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200
Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.
-
2 weeks ago benzinga.com
TwinStrand Biosciences Announces U.S. Patent And Trademark Office's Patent Trial And Appeal Board Rejects Guardant Health's Challenge To Core Patent Underlying Duplex Sequencing
TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected…
-
2 weeks ago benzinga.com
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.
-
3 weeks ago benzinga.com
Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH
Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographiesThis latest approval marks Guardant’s 31st CDx approval
-
3 weeks ago benzinga.com
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.
3 weeks ago benzinga.com
S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today
S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
-
3 weeks ago benzinga.com
Guardant Health Announces Results From Its COSMOS-MEL01 Trial Shows 81% Sensitivity For Distant Recurrence, 100% Post-Treatment Facility
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published…
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200
Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $200.
-
1 month ago benzinga.com
Guardant Health’s Shield Blood Test For Colorectal Cancer Screening To Be Covered In EviCore By Evernorth Clinical Guidelines Effective January 1, 2027, Per ACS Guidelines
Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersMilestone marks rapid…
-
1 month ago benzinga.com
UBS Maintains Buy on Guardant Health, Raises Price Target to $225
UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.
-
1 month ago benzinga.com
Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203
Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.
2 months ago benzinga.com
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
-
2 months ago benzinga.com
Carelon Health Services To Cover Guardant Health’s Shield Blood Test
Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersIncreasing total covered Shield…
2 months ago benzinga.com
Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech
Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.
-
2 months ago benzinga.com
Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193
Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $135 to $193.
-
2 months ago benzinga.com
Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195
Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.
-
2 months ago benzinga.com
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $175 to $185.
-
3 months ago benzinga.com
Stifel Maintains Buy on Guardant Health, Raises Price Target to $180
Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $130 to $180.
-
3 months ago benzinga.com
RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200
RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $185 to $200.
-
3 months ago benzinga.com
Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $200
Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $175 to $200.
-
3 months ago benzinga.com
JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $195
JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $195.
-
3 months ago benzinga.com
TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $210
TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $200 to $210.
3 months ago benzinga.com
AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday
U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other gainers include NWL, FET, IESC, SPXC, AMZN, SPSC, DLB, GH, DXCM, and MPWR.
3 months ago benzinga.com
Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For Friday
Analysts change outlook & price targets for Crocs, Monolithic Power, Axos Financial, Amazon, Karyopharm, Apple, Guardant Health, Pagaya Tech.
-
3 months ago benzinga.com
BTIG Maintains Buy on Guardant Health, Raises Price Target to $195
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $195.
3 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's after-market session. The market value of their outstanding shares is at $297.1 million. uniQure…
-
3 months ago benzinga.com
Guardant Health Raises FY2026 Sales Guidance from $1.300B-$1.320B to $1.340B-$1.360B vs $1.314B Est
Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.300 billion-$1.320 billion to $1.340 billion-$1.360 billion vs $1.314 billion estimate.
-
3 months ago benzinga.com
Guardant Health Q2 Adj. EPS $(0.42) Misses $(0.41) Estimate, Sales $334.978M Beat $314.226M Estimate
Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.41) by 2.44 percent. This is a 4.55 percent increase over losses of…
-
3 months ago benzinga.com
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $190
Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $160 to $190.
-
3 months ago benzinga.com
Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $205
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $205.
-
3 months ago benzinga.com
Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $175
Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $130 to $175.
-
3 months ago benzinga.com
Citigroup Maintains Buy on Guardant Health, Raises Price Target to $215
Citigroup analyst Patrick Donnelly maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $150 to $215.
-
3 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Guardant Health, Raises Price Target to $200
Evercore ISI Group analyst Vijay Kumar maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $160 to $200.
-
3 months ago benzinga.com
B of A Securities Maintains Buy on Guardant Health, Raises Price Target to $190
B of A Securities analyst Michael Ryskin maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $190.
-
4 months ago benzinga.com
Bernstein Maintains Outperform on Guardant Health, Raises Price Target to $200
Bernstein analyst Eve Burstein maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $175 to $200.
-
4 months ago benzinga.com
BTIG Maintains Buy on Guardant Health, Raises Price Target to $190
BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $160 to $190.
-
4 months ago benzinga.com
Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $160
Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $160.
-
4 months ago benzinga.com
Bernstein Reinstates Outperform on Guardant Health, Announces $175 Price Target
Bernstein analyst Eve Burstein reinstates Guardant Health (NASDAQ:GH) with a Outperform and announces $175 price target.
-
4 months ago benzinga.com
Barclays Maintains Overweight on Guardant Health, Raises Price Target to $150
Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $120 to $150.
-
4 months ago benzinga.com
RBC Capital Initiates Coverage On Guardant Health with Outperform Rating, Announces Price Target of $185
RBC Capital analyst Dan Leonard initiates coverage on Guardant Health (NASDAQ:GH) with a Outperform rating and announces Price Target of $185.
-
4 months ago benzinga.com
Guardant Health Says FDA Approves Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim's HERNEXEOS
Blood-based liquid biopsy test enables identification of patients eligible for treatment with HERNEXEOS® (zongertinib tablets)Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company,…
-
4 months ago benzinga.com
Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $175
Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $135 to $175.
-
4 months ago benzinga.com
Goldman Sachs Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $165
Goldman Sachs analyst Evie Koslosky initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $165.
5 months ago benzinga.com
CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, HPQ target raised, PRAX target cut, GNSS target raised, INTU target lowered, GH target raised, CRDO…
5 months ago benzinga.com
This Evercore ISI Group Analyst Turns Bullish; Here Are Top 2 Upgrades For Tuesday
Top Wall Street analysts upgraded GH to Outperform and raised price target to $160. Other analysts also have positive views on GH stock.